1.Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications
Kwang Hyun CHUNG ; Jaihwan KIM
Korean Journal of Pancreas and Biliary Tract 2026;31(1):1-7
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated remarkable efficacy in the management of diabetes and obesity; however, their potential association with acute pancreatitis has been debated since their early clinical use. Numerous cases of suspected GLP-1 RA-related pancreatitis have been reported in the literature and pharmacovigilance databases, raising concerns about their safety. This review aims to examine the clinical and mechanistic evidence linking GLP-1 RA use to acute pancreatitis, including recent clinical studies, meta-analyses, and pathophysiological investigations. Based on the latest clinical evidence and practice guidelines, we propose strategies for the safe and appropriate use of GLP-1 RAs in clinical practice.
2.Superior Efficacy of Bismuth-Containing Rifabutin Quadruple Therapy over Rifabutin Triple Therapy as Salvage Treatment
Hannah LEE ; Jun-Won CHUNG ; Kyoung Oh KIM ; Kwang An KWON ; Jung Ho KIM
Gut and Liver 2026;20(1):69-76
Background/Aims:
Helicobacter pylori is a pathogen that causes chronic gastritis and peptic ulcer diseases and is a carcinogen responsible for the development of malignancies, including gastric cancer. In the current era of high antimicrobial resistance, rifabutin-based triple therapy is recommended as a salvage therapy. Bismuth has not only a strong bacteriostatic effect but also a synergic effect when combined with antibiotics. Our study aimed to compare and evaluate the eradication rates between rifabutin-based triple therapy and rifabutin with bismuth-containing quadruple therapy as salvage treatments.
Methods:
In this single-center study, patients who received rifabutin-based triple therapy and rifabutin with bismuth-containing quadruple therapy after failure of conventional therapy, including first- and second-line treatment, between January 2016 and July 2024, were retrospectively investigated. A total of 53 patients who received rifabutin-based triple therapy and 50 who received bismuth-containing quadruple therapy were included.
Results:
In the rifabutin-based triple therapy group, eradication was achieved in 32 out of 53 patients (60.4%; 95% confidence interval [CI], 46.8% to 74.0%). In the bismuth-containing quadruple therapy group, eradication was achieved in 40 out of 50 patients (80.0%; 95% CI, 68.5% to 91.5%), demonstrating significant therapeutic benefit (p=0.030). Adverse events, including nausea, epigastric discomfort, and lethargy, were significantly more frequent in the bismuth-containing quadruple therapy group (p=0.007), but they were mild and tolerable enough not to affect compliance (p=0.329).
Conclusions
Rifabutin with bismuth-containing quadruple regimen as a salvage treatment achieved significantly superior eradication efficacy over the rifabutin-based triple regimen. Further multicenter prospective studies are needed to provide additional supporting evidence.
3.Microwave ablation vs. liver resection for patients with hepatocellular carcinomas
Hyundam GU ; Yeonjoo SEO ; Dong Jin CHUNG ; Kwang Yeol PAIK ; Seung Kew YOON ; Jihye LIM
Journal of Liver Cancer 2025;25(1):99-108
Background:
s/Aims: Microwave ablation (MWA) is an emerging ablative therapy that surpasses previous methods by achieving higher temperatures and creating larger ablation zones within shorter periods. This study compared the therapeutic outcomes of MWA with those of liver resection in real-world clinical practice.
Methods:
A total of 178 patients with 259 nodules who underwent MWA or liver resection between January 2015 and July 2023 were enrolled. Local tumor progression (LTP)-free survival, overall progression (OP)-free survival, and overall survival (OS) were assessed based on the treatment modality for the index nodule.
Results:
Of the 178 patients, 134 with 214 nodules underwent MWA, and 44 with 45 nodules underwent liver resection. The median follow-up period was 2.0±1.5 years. The annual incidence of LTP was 3.7% for MWA and 1.4% for liver resection. Treatment modality did not significantly affect LTP-free survival (hazard ratio, 0.61; 95% confidence interval, 0.14-2.69; P=0.511). For nodules larger than 3 cm, LTP-free survival was not affected by the treatment modality. Similarly, OP-free survival and OS were not influenced by treatment modality.
Conclusions
MWA and liver resection demonstrated comparable treatment outcomes in terms of local tumor control, overall recurrence, and survival. MWA may be an alternative treatment option for select patients; however, further studies are necessary to generalize these findings.
4.Microwave ablation vs. liver resection for patients with hepatocellular carcinomas
Hyundam GU ; Yeonjoo SEO ; Dong Jin CHUNG ; Kwang Yeol PAIK ; Seung Kew YOON ; Jihye LIM
Journal of Liver Cancer 2025;25(1):99-108
Background:
s/Aims: Microwave ablation (MWA) is an emerging ablative therapy that surpasses previous methods by achieving higher temperatures and creating larger ablation zones within shorter periods. This study compared the therapeutic outcomes of MWA with those of liver resection in real-world clinical practice.
Methods:
A total of 178 patients with 259 nodules who underwent MWA or liver resection between January 2015 and July 2023 were enrolled. Local tumor progression (LTP)-free survival, overall progression (OP)-free survival, and overall survival (OS) were assessed based on the treatment modality for the index nodule.
Results:
Of the 178 patients, 134 with 214 nodules underwent MWA, and 44 with 45 nodules underwent liver resection. The median follow-up period was 2.0±1.5 years. The annual incidence of LTP was 3.7% for MWA and 1.4% for liver resection. Treatment modality did not significantly affect LTP-free survival (hazard ratio, 0.61; 95% confidence interval, 0.14-2.69; P=0.511). For nodules larger than 3 cm, LTP-free survival was not affected by the treatment modality. Similarly, OP-free survival and OS were not influenced by treatment modality.
Conclusions
MWA and liver resection demonstrated comparable treatment outcomes in terms of local tumor control, overall recurrence, and survival. MWA may be an alternative treatment option for select patients; however, further studies are necessary to generalize these findings.
5.Microwave ablation vs. liver resection for patients with hepatocellular carcinomas
Hyundam GU ; Yeonjoo SEO ; Dong Jin CHUNG ; Kwang Yeol PAIK ; Seung Kew YOON ; Jihye LIM
Journal of Liver Cancer 2025;25(1):99-108
Background:
s/Aims: Microwave ablation (MWA) is an emerging ablative therapy that surpasses previous methods by achieving higher temperatures and creating larger ablation zones within shorter periods. This study compared the therapeutic outcomes of MWA with those of liver resection in real-world clinical practice.
Methods:
A total of 178 patients with 259 nodules who underwent MWA or liver resection between January 2015 and July 2023 were enrolled. Local tumor progression (LTP)-free survival, overall progression (OP)-free survival, and overall survival (OS) were assessed based on the treatment modality for the index nodule.
Results:
Of the 178 patients, 134 with 214 nodules underwent MWA, and 44 with 45 nodules underwent liver resection. The median follow-up period was 2.0±1.5 years. The annual incidence of LTP was 3.7% for MWA and 1.4% for liver resection. Treatment modality did not significantly affect LTP-free survival (hazard ratio, 0.61; 95% confidence interval, 0.14-2.69; P=0.511). For nodules larger than 3 cm, LTP-free survival was not affected by the treatment modality. Similarly, OP-free survival and OS were not influenced by treatment modality.
Conclusions
MWA and liver resection demonstrated comparable treatment outcomes in terms of local tumor control, overall recurrence, and survival. MWA may be an alternative treatment option for select patients; however, further studies are necessary to generalize these findings.
6.Asian Federation of Osteoporosis Societies 2025 consensus on atypical femoral fractures in patients with osteoporosis
Thanut VALLEENUKUL ; Thawee SONGPATANASILP ; Unnop JAISAMRARN ; Surapong ANURAKLEKHA ; Varalak SRINONPRASERT ; Sumapa CHAIAMNUAY ; Aasis UNNANUNTANA ; Lalita WATTANACHANYA ; Hataikarn NIMITPHONG ; Noratep KULACHOTE ; Ong-art PHRUETTHIPHAT ; Rahat JARAYABHAND ; Tanawat AMPHANSAP ; Ekasame VANITCHAROENKUL ; Pojchong CHOTIYARNWONG ; Satoshi MORI ; Kwang-kyoun KIM ; Swan Sim YEAP ; Sharmila Sunita PARAMASIVAM ; Linsey GANI ; Ching-Lung CHEUNG ; Julie LI-YU ; Mark Anthony SANDOVAL ; Chung-Hwan CHEN ; Natthinee CHARATCHAROENWITTHAYA
Osteoporosis and Sarcopenia 2025;11(4):111-120
Atypical femoral fractures (AFFs) are a rare but serious complication of prolonged anti-resorptive therapy for osteoporosis. This study aimed to develop consensus-based recommendations for the clinical management of AFFs across the Asian Federation of Osteoporosis Societies (AFOS), for harmonizing practice and improving patient outcomes.A structured questionnaire covering ten key domains related to AFFs was distributed to expert representatives from the 10 AFOS member countries or regions. Responses were analyzed to identify areas of consensus and variation in regional practice. A concurrent narrative review of the literature was conducted to inform evidencebased recommendations. Survey responses were obtained from 8 of 10 participating AFOS member nations or regions. Among these, Thailand, Malaysia, South Korea, and Hong Kong reported established national guidelines or position statements on AFFs. Contributing risk factors include extended anti-resorptive therapy, femoral geometry, comorbidities, and specific pharmacologic exposures. Diagnosis depends on clinical suspicion and multimodal imaging, with high concordance in diagnostic criteria across regions. Screening emphasizes full-length femoral imaging in highrisk individuals. Incomplete AFFs are managed conservatively or with prophylactic fixation, while complete AFFs typically require intramedullary nailing, tailored to anatomic variations such as femoral bowing. Post-fracture care involves discontinuation of anti-resorptives, assessment for secondary osteoporosis, and potential initia tion of anabolic therapy, including teriparatide, abaloparatide, and romosozumab.This AFOS-led initiative highlights the importance for early detection, individualized management, and region-specific strategies. A multidisciplinary, patient-centered approach—encompassing risk assessment, im aging surveillance, surgical intervention, and tailored pharmacologic treatment—is crucial to reduce AFFs impact and improve skeletal health outcomes across Asia.
7.Current status of treatment for esophagojejunostomy leakage after total gastrectomy in patients with gastric cancer: a multicenter retrospective study in Korea
Min-Chan KIM ; Mi Ran JUNG ; Jeong Ju NOH ; Sunghwa KANG ; Jae Hun CHUNG ; Ji-Ho PARK ; Tae-Han KIM ; Jae Kyun PARK ; Yoonhong KIM ; Sang Hyuk SEO ; Sung Eun KIM ; Oh Kyung KWON ; Ji Yeon PARK ; Ki Bum PARK ; Sun-Hwi HWANG ; SI-Hak LEE ; Young-Joon LEE ; Sang-Ho JEONG ; Tae-Yong JEON ; Dae Hwan KIM ; Chang In CHOI ; Ki Young YOON ; Kyung Won SEO ; Ki Hyun KIM ; Sang Hoon OH ; Kwang Hee KIM
Journal of Minimally Invasive Surgery 2025;28(4):184-192
Purpose:
Esophagojejunostomy leakage (EJL) remains one of the most critical complications following total gastrectomy for gastric cancer. This study aimed to evaluate the evolving therapeutic approaches and clinical outcomes of EJL using data from a large-scale multicenter retrospective cohort.
Methods:
Among 6,577 patients who underwent total gastrectomy or proximal gastrectomy with double tract reconstruction at nine institutions from 2003 to 2024, 196 (3.0%) developed EJL. Of these, 162 patients with comprehensive clinical data were included in the final analysis. The study examined treatment modalities, changes in management over time, patient characteristics, surgical variables, and clinical outcomes. Four groups were defined according to treatment approach: conservative, endoscopic, reoperation, and multimodal (combined) therapy.
Results:
Endoscopic therapy was first introduced in 2011 and has progressively supplanted reoperation, now comprising 32.5% of cases. The average time to EJL diagnosis was 8.4 days after surgery. Overall in-hospital mortality was 6.1% (10/162). When conservative management was excluded, endoscopic treatment demonstrated the highest rate of therapeutic success (94.3%, p = 0.004). Both the duration until diet resumption and length of hospital stay were notably reduced in the endoscopic and conservative groups compared with reoperation and multimodal therapy (p < 0.001). Moreover, although the highest post-leakage hospitalization costs were observed with multimodal treatment (p < 0.001), overall hospitalization expenses were significantly lower for patients managed conservatively or with endoscopic intervention (p < 0.001).
Conclusion
Over the past two decades, management of EJL has shifted toward endoscopic approaches. Endoscopic therapies yield superior clinical outcomes and should be considered a primary option for appropriate candidates.
8.Patients participation in multidisciplinary management in gastric cancer: regulation comparison and expert survey among major countries
Kyoyoung PARK ; Hyuk-Joon LEE ; Seong-Ho KONG ; Do Joong PARK ; Hyunsoo CHUNG ; Soo-Jeong CHO ; Seock-Ah IM ; Yoonjin KWAK ; Hye Seung LEE ; Eui Kyu CHIE ; Jimmy Bok Yan SO ; Zekuan XU ; Narikazu BOKU ; Jiafu JI ; Yuko KITAGAWA ; Raul J ROSENTHAL ; Takeshi SANO ; Han-Kwang YANG
Korean Journal of Clinical Oncology 2025;21(3):143-149
Purpose:
In Korea, the Health Insurance Review and Assessment Service (HIRA) mandates patient participation in outpatient multidisciplinary team (MDT) meetings as part of national cancer quality assessment. However, the necessity of involving patients and families in MDT discussions remains debatable. This study explored international expert perspectives on patient participation in gastric cancer MDTs.
Methods:
A cross-national expert survey was conducted in September 2021 among 15 gastric cancer specialists from Korea, China, Japan, Singapore, and the United States. The survey assessed the frequency of patient and family member attendance, perceived pros and cons, and preferences regarding mandatory versus selective involvement. Additionally, MDT structures and policies were reviewed by countries.
Results:
Most respondents reported that patients and families rarely or never attend MDT meetings: nine stated that patients are never included, three reported “usually not,” and three indicated “sometimes.” None consistently included patients. The most cited benefits were sharing opinions with patients and families simultaneously, followed by improved explanation of treatment and legal protection. Major concerns included hindered discussion, inefficiency, and logistical challenges. Only four respondents supported routine participation, while 11 favored case-dependent involvement.
Conclusion
International experts do not widely support mandatory patient participation in MDT meetings. A flexible approach that allows MDTs to operate with or without patient involvement may better reflect actual clinical practice.
9.Effect of Home-Based Transcranial Direct Current Stimulation on Cognitive Function in Patients with Mild Cognitive Impairment: A Two-Week Intervention
Jaesub PARK ; Kyungmi CHUNG ; Yoonkyung OH ; Kwang Joon KIM ; Chang Oh KIM ; Jin Young PARK
Yonsei Medical Journal 2024;65(6):341-347
Purpose:
Repeated transcranial direct current stimulation (tDCS) is expected to have the potential to improve cognitive function in patients with mild cognitive impairment (MCI). We aimed to evaluate the efficacy and safety of at-home tDCS for elderly patients with MCI.
Materials and Methods:
Patients aged 60–80 years, who maintained normal daily living but reported objective memory impairments, were enrolled. Active or sham stimulations were applied to the dorsal frontal cortex (left: anode; right: cathode) at home for 2 weeks. Changes in cognitive function were assessed using visual recognition tasks and the Mini-Mental State Exam (MMSE), and safety and efficacy were assessed using self-reports and a remote monitoring application.
Results:
Of the 19 participants enrolled, 12 participants were included in the efficacy analysis. Response times and MMSE scores significantly improved after active stimulation compared to the sham stimulation; however, there were no significant differences in the proportion of correct responses. The mean compliance of the efficacy group was 97.5%±4.1%. Three participants experienced burns, but no permanent sequelae remained.
Conclusion
This preliminary result suggests that home-based tDCS may be a promising treatment option for MCI patients; however, it requires more attention and technological development to address safety concerns.
10.1,064-nm and 532-nm picosecond neodymium-doped:yttrium-aluminum-garnet laser treatment for longitudinal melanonychia: a case report
Hye Sung HAN ; Yoon Hwan LEE ; Ka Ram KIM ; Young Gue KOH ; Sun Young CHOI ; Kwang Ho YOO
Medical Lasers 2024;13(1):63-65
Melanonychia is a common pigmentary disorder characterized by black or brownish longitudinal pigmentation of the nail plate. It is usually benign but can cause aesthetic concerns. Herein, we describe the case of a 29-year-old female diagnosed with benign longitudinal melanonychia, and treated with two different wavelengths of picosecond neodymium-doped:yttrium-aluminum-garnet (ps Nd:YAG) laser. The lesion was divided into two halves. The proximal half was treated with a 1,064-nm ps Nd:YAG laser and the distal half was treated with a 532-nm ps Nd:YAG laser. After a single treatment session, both sides exhibited immediate and marked improvement. However, after three weeks pigmentation that had grown out from the nail matrix was evident on the proximal nail plate. This case suggests that ps Nd:YAG lasers may be effective for immediate resolution of pigmentation on the nail plate, but fundamental treatment of the nail matrix is necessary to prevent recurrence.

Result Analysis
Print
Save
E-mail